Review





Similar Products

fty720  (MedChemExpress)
97
MedChemExpress fty720
TRANS enhances tumoral T cell abundance and synergizes with immune checkpoint inhib itors. (A) UMAP visualization of lymphocytes in the TME following PBS or TRANS treatment. (B) UMAP visualization of lymphocyte clusters. (C) Proportional distribution of lymphocyte clusters. (D) Expression of cluster-specific marker genes. (E) Top 10 maker genes in CD8 + effector T cells (Teff). (F) Volcano plot of differentially expressed genes in CD8 + Teff between TRANS and PBS. (G) Dot plot showing upregulated pathways in IFN-γ + T cells (TRANS vs PBS), with dot size reflecting KEGG enrichment intensity. (H) Dot plot of ligand-receptor interactions between myeloid cells and T cells (TRANS vs PBS). Ligands (blue) and receptors (red) are labeled. (I) Experimental design of tumor therapy by TRANS combination with <t>FTY720.</t> (J) Tumor growth curve in mice treated with PBS, TRANS, and FTY720+TRANS; n = 5. (K – M) Tumor-infiltrating CD4 + and CD8 + T cells (K), Granzyme + CD8 + T or IFN-γ + CD8 + T cells counts (L), and Exhausted T cells (M) in TME; n = 5. (N) Scheme of tumor therapy by TRANS combined with immune checkpoint inhibitors (ICI). (O and P) Individual tumor changes (O) and Survival rate (Q) of tumor-bearing mice with different treatments; n = 5. (Q and R) Ex vivo IFN-γ expression (Q) and Quantification (R) in splenic CD8 + T cells with PMA/ionomycin stimulation; n = 3. (S) IFN-γ secretion by splenic T cells following αCD3/αCD28 stimulation; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
Fty720, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fty720/Fingolimod+hydrochloride/pmc12996997-359-0-11
Average 97 stars, based on 1 article reviews
fty720 - by Bioz Stars, 2026-10
97/100 stars
  Buy from Supplier
fty720 treatment  (TargetMol)
94
TargetMol fty720 treatment
TRANS enhances tumoral T cell abundance and synergizes with immune checkpoint inhib itors. (A) UMAP visualization of lymphocytes in the TME following PBS or TRANS treatment. (B) UMAP visualization of lymphocyte clusters. (C) Proportional distribution of lymphocyte clusters. (D) Expression of cluster-specific marker genes. (E) Top 10 maker genes in CD8 + effector T cells (Teff). (F) Volcano plot of differentially expressed genes in CD8 + Teff between TRANS and PBS. (G) Dot plot showing upregulated pathways in IFN-γ + T cells (TRANS vs PBS), with dot size reflecting KEGG enrichment intensity. (H) Dot plot of ligand-receptor interactions between myeloid cells and T cells (TRANS vs PBS). Ligands (blue) and receptors (red) are labeled. (I) Experimental design of tumor therapy by TRANS combination with <t>FTY720.</t> (J) Tumor growth curve in mice treated with PBS, TRANS, and FTY720+TRANS; n = 5. (K – M) Tumor-infiltrating CD4 + and CD8 + T cells (K), Granzyme + CD8 + T or IFN-γ + CD8 + T cells counts (L), and Exhausted T cells (M) in TME; n = 5. (N) Scheme of tumor therapy by TRANS combined with immune checkpoint inhibitors (ICI). (O and P) Individual tumor changes (O) and Survival rate (Q) of tumor-bearing mice with different treatments; n = 5. (Q and R) Ex vivo IFN-γ expression (Q) and Quantification (R) in splenic CD8 + T cells with PMA/ionomycin stimulation; n = 3. (S) IFN-γ secretion by splenic T cells following αCD3/αCD28 stimulation; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
Fty720 Treatment, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fty720/Fingolimod/pm41904143-334-2-6
Average 94 stars, based on 1 article reviews
fty720 treatment - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
modulator fty720 targets sphingosine 1 phosphate receptors  (Brinkmann Instruments)
86
Brinkmann Instruments modulator fty720 targets sphingosine 1 phosphate receptors
TRANS enhances tumoral T cell abundance and synergizes with immune checkpoint inhib itors. (A) UMAP visualization of lymphocytes in the TME following PBS or TRANS treatment. (B) UMAP visualization of lymphocyte clusters. (C) Proportional distribution of lymphocyte clusters. (D) Expression of cluster-specific marker genes. (E) Top 10 maker genes in CD8 + effector T cells (Teff). (F) Volcano plot of differentially expressed genes in CD8 + Teff between TRANS and PBS. (G) Dot plot showing upregulated pathways in IFN-γ + T cells (TRANS vs PBS), with dot size reflecting KEGG enrichment intensity. (H) Dot plot of ligand-receptor interactions between myeloid cells and T cells (TRANS vs PBS). Ligands (blue) and receptors (red) are labeled. (I) Experimental design of tumor therapy by TRANS combination with <t>FTY720.</t> (J) Tumor growth curve in mice treated with PBS, TRANS, and FTY720+TRANS; n = 5. (K – M) Tumor-infiltrating CD4 + and CD8 + T cells (K), Granzyme + CD8 + T or IFN-γ + CD8 + T cells counts (L), and Exhausted T cells (M) in TME; n = 5. (N) Scheme of tumor therapy by TRANS combined with immune checkpoint inhibitors (ICI). (O and P) Individual tumor changes (O) and Survival rate (Q) of tumor-bearing mice with different treatments; n = 5. (Q and R) Ex vivo IFN-γ expression (Q) and Quantification (R) in splenic CD8 + T cells with PMA/ionomycin stimulation; n = 3. (S) IFN-γ secretion by splenic T cells following αCD3/αCD28 stimulation; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
Modulator Fty720 Targets Sphingosine 1 Phosphate Receptors, supplied by Brinkmann Instruments, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fty720/1+fty720+modulator+phosphate+receptors+sphingosine+targets/pm42268470-257-35-6
Average 86 stars, based on 1 article reviews
modulator fty720 targets sphingosine 1 phosphate receptors - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
immunosuppressive drug fty720  (Novartis)
86
Novartis immunosuppressive drug fty720
TRANS enhances tumoral T cell abundance and synergizes with immune checkpoint inhib itors. (A) UMAP visualization of lymphocytes in the TME following PBS or TRANS treatment. (B) UMAP visualization of lymphocyte clusters. (C) Proportional distribution of lymphocyte clusters. (D) Expression of cluster-specific marker genes. (E) Top 10 maker genes in CD8 + effector T cells (Teff). (F) Volcano plot of differentially expressed genes in CD8 + Teff between TRANS and PBS. (G) Dot plot showing upregulated pathways in IFN-γ + T cells (TRANS vs PBS), with dot size reflecting KEGG enrichment intensity. (H) Dot plot of ligand-receptor interactions between myeloid cells and T cells (TRANS vs PBS). Ligands (blue) and receptors (red) are labeled. (I) Experimental design of tumor therapy by TRANS combination with <t>FTY720.</t> (J) Tumor growth curve in mice treated with PBS, TRANS, and FTY720+TRANS; n = 5. (K – M) Tumor-infiltrating CD4 + and CD8 + T cells (K), Granzyme + CD8 + T or IFN-γ + CD8 + T cells counts (L), and Exhausted T cells (M) in TME; n = 5. (N) Scheme of tumor therapy by TRANS combined with immune checkpoint inhibitors (ICI). (O and P) Individual tumor changes (O) and Survival rate (Q) of tumor-bearing mice with different treatments; n = 5. (Q and R) Ex vivo IFN-γ expression (Q) and Quantification (R) in splenic CD8 + T cells with PMA/ionomycin stimulation; n = 3. (S) IFN-γ secretion by splenic T cells following αCD3/αCD28 stimulation; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
Immunosuppressive Drug Fty720, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fty720/fty720/pm42041530-19-17-22
Average 86 stars, based on 1 article reviews
immunosuppressive drug fty720 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
sev fty720  (MedChemExpress)
97
MedChemExpress sev fty720
TRANS enhances tumoral T cell abundance and synergizes with immune checkpoint inhib itors. (A) UMAP visualization of lymphocytes in the TME following PBS or TRANS treatment. (B) UMAP visualization of lymphocyte clusters. (C) Proportional distribution of lymphocyte clusters. (D) Expression of cluster-specific marker genes. (E) Top 10 maker genes in CD8 + effector T cells (Teff). (F) Volcano plot of differentially expressed genes in CD8 + Teff between TRANS and PBS. (G) Dot plot showing upregulated pathways in IFN-γ + T cells (TRANS vs PBS), with dot size reflecting KEGG enrichment intensity. (H) Dot plot of ligand-receptor interactions between myeloid cells and T cells (TRANS vs PBS). Ligands (blue) and receptors (red) are labeled. (I) Experimental design of tumor therapy by TRANS combination with <t>FTY720.</t> (J) Tumor growth curve in mice treated with PBS, TRANS, and FTY720+TRANS; n = 5. (K – M) Tumor-infiltrating CD4 + and CD8 + T cells (K), Granzyme + CD8 + T or IFN-γ + CD8 + T cells counts (L), and Exhausted T cells (M) in TME; n = 5. (N) Scheme of tumor therapy by TRANS combined with immune checkpoint inhibitors (ICI). (O and P) Individual tumor changes (O) and Survival rate (Q) of tumor-bearing mice with different treatments; n = 5. (Q and R) Ex vivo IFN-γ expression (Q) and Quantification (R) in splenic CD8 + T cells with PMA/ionomycin stimulation; n = 3. (S) IFN-γ secretion by splenic T cells following αCD3/αCD28 stimulation; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
Sev Fty720, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fty720/Fingolimod/pm41981595-84-70-75
Average 97 stars, based on 1 article reviews
sev fty720 - by Bioz Stars, 2026-10
97/100 stars
  Buy from Supplier
fty720  (Brinkmann Instruments)
86
Brinkmann Instruments fty720
TRANS enhances tumoral T cell abundance and synergizes with immune checkpoint inhib itors. (A) UMAP visualization of lymphocytes in the TME following PBS or TRANS treatment. (B) UMAP visualization of lymphocyte clusters. (C) Proportional distribution of lymphocyte clusters. (D) Expression of cluster-specific marker genes. (E) Top 10 maker genes in CD8 + effector T cells (Teff). (F) Volcano plot of differentially expressed genes in CD8 + Teff between TRANS and PBS. (G) Dot plot showing upregulated pathways in IFN-γ + T cells (TRANS vs PBS), with dot size reflecting KEGG enrichment intensity. (H) Dot plot of ligand-receptor interactions between myeloid cells and T cells (TRANS vs PBS). Ligands (blue) and receptors (red) are labeled. (I) Experimental design of tumor therapy by TRANS combination with <t>FTY720.</t> (J) Tumor growth curve in mice treated with PBS, TRANS, and FTY720+TRANS; n = 5. (K – M) Tumor-infiltrating CD4 + and CD8 + T cells (K), Granzyme + CD8 + T or IFN-γ + CD8 + T cells counts (L), and Exhausted T cells (M) in TME; n = 5. (N) Scheme of tumor therapy by TRANS combined with immune checkpoint inhibitors (ICI). (O and P) Individual tumor changes (O) and Survival rate (Q) of tumor-bearing mice with different treatments; n = 5. (Q and R) Ex vivo IFN-γ expression (Q) and Quantification (R) in splenic CD8 + T cells with PMA/ionomycin stimulation; n = 3. (S) IFN-γ secretion by splenic T cells following αCD3/αCD28 stimulation; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
Fty720, supplied by Brinkmann Instruments, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fty720/1+receptor+s1p/pm41941276-93-13-17
Average 86 stars, based on 1 article reviews
fty720 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
fty720  (TargetMol)
94
TargetMol fty720
TRANS enhances tumoral T cell abundance and synergizes with immune checkpoint inhib itors. (A) UMAP visualization of lymphocytes in the TME following PBS or TRANS treatment. (B) UMAP visualization of lymphocyte clusters. (C) Proportional distribution of lymphocyte clusters. (D) Expression of cluster-specific marker genes. (E) Top 10 maker genes in CD8 + effector T cells (Teff). (F) Volcano plot of differentially expressed genes in CD8 + Teff between TRANS and PBS. (G) Dot plot showing upregulated pathways in IFN-γ + T cells (TRANS vs PBS), with dot size reflecting KEGG enrichment intensity. (H) Dot plot of ligand-receptor interactions between myeloid cells and T cells (TRANS vs PBS). Ligands (blue) and receptors (red) are labeled. (I) Experimental design of tumor therapy by TRANS combination with <t>FTY720.</t> (J) Tumor growth curve in mice treated with PBS, TRANS, and FTY720+TRANS; n = 5. (K – M) Tumor-infiltrating CD4 + and CD8 + T cells (K), Granzyme + CD8 + T or IFN-γ + CD8 + T cells counts (L), and Exhausted T cells (M) in TME; n = 5. (N) Scheme of tumor therapy by TRANS combined with immune checkpoint inhibitors (ICI). (O and P) Individual tumor changes (O) and Survival rate (Q) of tumor-bearing mice with different treatments; n = 5. (Q and R) Ex vivo IFN-γ expression (Q) and Quantification (R) in splenic CD8 + T cells with PMA/ionomycin stimulation; n = 3. (S) IFN-γ secretion by splenic T cells following αCD3/αCD28 stimulation; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
Fty720, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fty720/Fingolimod/pm41904143-334-5-6
Average 94 stars, based on 1 article reviews
fty720 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
fty720  (Merck & Co)
86
Merck & Co fty720
TRANS enhances tumoral T cell abundance and synergizes with immune checkpoint inhib itors. (A) UMAP visualization of lymphocytes in the TME following PBS or TRANS treatment. (B) UMAP visualization of lymphocyte clusters. (C) Proportional distribution of lymphocyte clusters. (D) Expression of cluster-specific marker genes. (E) Top 10 maker genes in CD8 + effector T cells (Teff). (F) Volcano plot of differentially expressed genes in CD8 + Teff between TRANS and PBS. (G) Dot plot showing upregulated pathways in IFN-γ + T cells (TRANS vs PBS), with dot size reflecting KEGG enrichment intensity. (H) Dot plot of ligand-receptor interactions between myeloid cells and T cells (TRANS vs PBS). Ligands (blue) and receptors (red) are labeled. (I) Experimental design of tumor therapy by TRANS combination with <t>FTY720.</t> (J) Tumor growth curve in mice treated with PBS, TRANS, and FTY720+TRANS; n = 5. (K – M) Tumor-infiltrating CD4 + and CD8 + T cells (K), Granzyme + CD8 + T or IFN-γ + CD8 + T cells counts (L), and Exhausted T cells (M) in TME; n = 5. (N) Scheme of tumor therapy by TRANS combined with immune checkpoint inhibitors (ICI). (O and P) Individual tumor changes (O) and Survival rate (Q) of tumor-bearing mice with different treatments; n = 5. (Q and R) Ex vivo IFN-γ expression (Q) and Quantification (R) in splenic CD8 + T cells with PMA/ionomycin stimulation; n = 3. (S) IFN-γ secretion by splenic T cells following αCD3/αCD28 stimulation; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
Fty720, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fty720/compound+fty720/pm41903139-250-10-11
Average 86 stars, based on 1 article reviews
fty720 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


TRANS enhances tumoral T cell abundance and synergizes with immune checkpoint inhib itors. (A) UMAP visualization of lymphocytes in the TME following PBS or TRANS treatment. (B) UMAP visualization of lymphocyte clusters. (C) Proportional distribution of lymphocyte clusters. (D) Expression of cluster-specific marker genes. (E) Top 10 maker genes in CD8 + effector T cells (Teff). (F) Volcano plot of differentially expressed genes in CD8 + Teff between TRANS and PBS. (G) Dot plot showing upregulated pathways in IFN-γ + T cells (TRANS vs PBS), with dot size reflecting KEGG enrichment intensity. (H) Dot plot of ligand-receptor interactions between myeloid cells and T cells (TRANS vs PBS). Ligands (blue) and receptors (red) are labeled. (I) Experimental design of tumor therapy by TRANS combination with FTY720. (J) Tumor growth curve in mice treated with PBS, TRANS, and FTY720+TRANS; n = 5. (K – M) Tumor-infiltrating CD4 + and CD8 + T cells (K), Granzyme + CD8 + T or IFN-γ + CD8 + T cells counts (L), and Exhausted T cells (M) in TME; n = 5. (N) Scheme of tumor therapy by TRANS combined with immune checkpoint inhibitors (ICI). (O and P) Individual tumor changes (O) and Survival rate (Q) of tumor-bearing mice with different treatments; n = 5. (Q and R) Ex vivo IFN-γ expression (Q) and Quantification (R) in splenic CD8 + T cells with PMA/ionomycin stimulation; n = 3. (S) IFN-γ secretion by splenic T cells following αCD3/αCD28 stimulation; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.

Journal: Bioactive Materials

Article Title: Chronic inflammation-responsive hydrogel restores myeloid-T cell crosstalk to reinvigorate antitumor immunity against metastatic colorectal cancer

doi: 10.1016/j.bioactmat.2026.03.012

Figure Lengend Snippet: TRANS enhances tumoral T cell abundance and synergizes with immune checkpoint inhib itors. (A) UMAP visualization of lymphocytes in the TME following PBS or TRANS treatment. (B) UMAP visualization of lymphocyte clusters. (C) Proportional distribution of lymphocyte clusters. (D) Expression of cluster-specific marker genes. (E) Top 10 maker genes in CD8 + effector T cells (Teff). (F) Volcano plot of differentially expressed genes in CD8 + Teff between TRANS and PBS. (G) Dot plot showing upregulated pathways in IFN-γ + T cells (TRANS vs PBS), with dot size reflecting KEGG enrichment intensity. (H) Dot plot of ligand-receptor interactions between myeloid cells and T cells (TRANS vs PBS). Ligands (blue) and receptors (red) are labeled. (I) Experimental design of tumor therapy by TRANS combination with FTY720. (J) Tumor growth curve in mice treated with PBS, TRANS, and FTY720+TRANS; n = 5. (K – M) Tumor-infiltrating CD4 + and CD8 + T cells (K), Granzyme + CD8 + T or IFN-γ + CD8 + T cells counts (L), and Exhausted T cells (M) in TME; n = 5. (N) Scheme of tumor therapy by TRANS combined with immune checkpoint inhibitors (ICI). (O and P) Individual tumor changes (O) and Survival rate (Q) of tumor-bearing mice with different treatments; n = 5. (Q and R) Ex vivo IFN-γ expression (Q) and Quantification (R) in splenic CD8 + T cells with PMA/ionomycin stimulation; n = 3. (S) IFN-γ secretion by splenic T cells following αCD3/αCD28 stimulation; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.

Article Snippet: FTY720, AMG 487, TAK-779, D-Mannitol, and hydroxypropyl-β-cyclodextrin (HP-β-CD) were provided by MedChemExpress (USA).

Techniques: Inhibition, Expressing, Marker, Labeling, Ex Vivo